Recombinant Human IL-3RA/CD123 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2013



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human IL-3RA protein Thr19-Arg305 (Accession# P26951-1) with a rabbit IgG Fc tag at the C-terminus.
GeneID 3563
Accession P26951-1
PredictedSize 59.4 kDa
SDS-PAGE 68-85 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Interleukin-3 receptor subunit alpha (IL-3R alpha), also known as CD123, belongs to the cytokine receptor family. It is a glycoprotein containing an extracellular domain, involving a predicted Ig-like domain, two FnIII domains, a transmembrane domain and an intracellular domain. IL-3R alpha is expressed on hematopoietic progenitor cells, plasmacytoid dendritic cells, basophils, monocytes, some B cells, and in a variety of hematologic malignancies. IL-3 initially binds to IL-3R alpha and subsequently recruits the beta chain (CD131) to form the high-affinity receptor, resulting in the activation of a series of signaling pathways including the JAK/STAT, Ras-MAPK, and phosphatidylinositol 3-kinase pathways (PMID: 29296749). IL-3R signaling regulates the proliferation, survival, and differentiation of hematopoietic cells.

References:

1. S Huang, et al. (1999). Stem Cells. 17(5):265-72. 2. Ugo Testa, et al. (2014). Biomark Res. 2(1):4. 3. Nicole L Wittwer, et al. (2017). Blood Adv. 1(15):1067-1079. 4. Adam J Lamble, et al. (2022). J Clin Oncol. 40(3):252-261.